Incidence of sinusoidal obstruction syndrome following Mylotarg (gemtuzumab ozogamicin): a prospective observational study of 482 patients in routine clinical practice
- 5 March 2013
- journal article
- Published by Springer Science and Business Media LLC in International Journal of Hematology
- Vol. 97 (4), 456-464
- https://doi.org/10.1007/s12185-013-1275-2
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Bone Marrow Progenitor Cells Repair Rat Hepatic Sinusoidal Endothelial Cells After Liver InjuryGastroenterology, 2009
- A problem-oriented approach to liver disease in oncology patientsGut, 2008
- Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): An overview from the research on adverse drug events and reports (RADAR) projectLeukemia Research, 2007
- The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patientsOncogene, 2007
- Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive diseaseBone Marrow Transplantation, 2002
- Toxic Injury to Hepatic Sinusoids: Sinusoidal Obstruction Syndrome (Veno-Occlusive Disease)Seminars in Liver Disease, 2002
- Management of Hepatic Sinusoidal Obstruction Syndrome Following Treatment with Gemtuzumab Ozogamicin (Mylotarg®)Clinical Lymphoma, 2002
- Mylotarg? (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantationCancer, 2001
- On the reliability of clinical criteria for the diagnosis of hepatic veno-occlusive diseaseAnnals of Hematology, 1993
- The biology of acute myeloblastic leukemia.1987